COVID-19 Frontline: Emerging Monoclonal Antibody Therapies and Vaccines for COVID-19: How They Work and When to Use Them MODULE 3: Overcoming Viral Mutations with Dual Monoclonal Antibody Therapy

Target Audience
The innovative continuing education and tools developed from COVID-19 FRONTLINE will be publicly available for the entire healthcare community to use. The whiteboard micro-learning modules will primarily target frontline doctors, such as emergency physicians, urgent care physicians, and intensive care physicians, with a secondary audience of primary care and family physicians.

Program Overview
This COVID-19 FRONTLINE Whiteboard series will explore the role of emerging monoclonal antibody therapies and vaccines in managing the COVID-19 pandemic. Each module will focus on clinical trial data and aid clinicians in identifying patients who would benefit from therapy.

In this module, we will investigate the risk of therapy failure due to SARS-CoV-2 mutation with single and dual monoclonal antibody therapies.

Learning Objective
Upon completion of this program, attendees should be better able to:

Compare the risk of therapy failure due to viral mutation between single and dual monoclonal antibody therapies and review the mechanism of action of monoclonal antibody therapies